A Phase 3 interventional study of Palivizumab in Respiratory Syncytial Virus Infection, sponsored by AbbVie (prior sponsor, Abbott). Completed at 6 sites in Japan. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2013-06-17.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Respiratory Syncytial Virus Infections with a site in Japan — 1 open to participants now, 5 under way, 2 of them phase 3. Respiratory Syncytial Virus Infections · Japan.
Among the 28 studies in Respiratory Syncytial Virus Infections with a site in Japan, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2011, is one of 9 in phase 3, and was the 1st registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 28 studies in Respiratory Syncytial Virus Infections with a site in Japan is open now. Recruiting first, the newest first:
Shionogi · Sites in Japan, United States, Argentina and 5 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: Up to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 12
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 28 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 183 across the 27 interventional studies, 1,100 across the 1 observational. Of the 23 that completed or were terminated, 19 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
AbbVie has 5 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Respiratory Syncytial Virus Infections with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07214571ShionogiA Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | 2026-12-30 |
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
| NCT06546800PfizerSPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER | 2027-10-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Respiratory Syncytial Virus Infections with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject must meet at least one of the following medical conditions (from [a] to [h]), and must be considered by the investigator to be a suitable candidate to receive prophylactic treatment of palivizumab:
Exclusion Criteria:
Subject who meets one of the palivizumab indications already approved in Japan.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
Drug: Palivizumab
Also known as: ABT-315, Synagis
Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121
Serum trough concentrations of palivizumab were assessed at Screening, at Day 31 (30 days after the 1st dose) and Day 121 (30 days after the 4th dose).
Time frame: Day 1 (Screening), Day 31, Day 121
Percentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection
Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Percentage of Participants Who Required Treatment for Respiratory Syncytial Virus (RSV) Infection
Percentage of participants who required any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.
Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Duration of Hospitalization Caused by Respiratory Syncytial Virus (RSV) Infection
Number of days of hospitalization caused by RSV infection.
Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Duration of Required Treatment for Respiratory Syncytial Virus (RSV) Infection
Duration (days) of requirement for any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.
Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs
An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.
Time frame: From the first administration of palivizumab to 100 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Mean Baseline and Mean Change From Baseline in Systolic/Diastolic Blood Pressure at Day 121
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Mean Baseline and Mean Change From Baseline in Body Temperature at Day 121
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Mean Baseline and Mean Change From Baseline in Respiratory Rate at Day 121
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Mean Baseline and Mean Change From Baseline in Pulse Rate at Day 121
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Mean Baseline and Mean Change From Baseline in Body Weight at Day 121
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Hematology: Mean Baseline and Mean Change From Baseline in Hemoglobin at Day 121
Normal range for hemoglobin varied by the monthly age of the participant.
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Hematology: Mean Baseline and Mean Change From Baseline in Hematocrit at Day 121
Normal range for hematocrit varied by the monthly age of the participant.
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Hematology: Mean Baseline and Mean Change From Baseline in White Blood Cells (WBC), Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes at Day 121
Normal ranges for WBC, neutrophils, eosinophils, basophils, lymphocytes, and monocytes varied by the monthly age of the participant.
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Hematology: Mean Baseline and Mean Change From Baseline in Red Blood Cells (RBC) and Platelet Count at Day 121
Normal ranges for RBC and platelet count varied by the monthly age of the participant.
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Blood Chemistry: Mean Baseline and Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) at Day 121
Normal ranges for ALP, AST, and ALT varied by the monthly age of the participant.
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Blood Chemistry: Mean Baseline and Change From Baseline in Total Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, and C-reactive Protein (CRP) at Day 121
Normal ranges for total bilirubin, BUN, creatinine, and CRP varied by the monthly age of the participant.
Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)
Urinalysis: Presence of Urine Protein, Glucose, and Occult Blood at Screening and Day 121
The values -, -/+, 1+, 2+, 3+, and 4+ represent a range from none (-) to highest (4+) presence of protein, glucose, and occult blood in the urine. Table presents the number of participants with each value. Those categories with 0 participants to report at either time point are not included in the table below.
Time frame: Screening, Day 121 (30 days after the 4th dose)
| Milestone | Palivizumab |
|---|---|
| Started | 28 |
| Completed | 26 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
Serum trough concentrations of palivizumab were assessed at Screening, at Day 31 (30 days after the 1st dose) and Day 121 (30 days after the 4th dose).
| µg/mL | Palivizumab |
|---|---|
| Day 1 (Screening); n=28 | 0 ± 0 |
| Day 31; n=28 | 59.0 ± 12.9 |
| Day 121; n=26 | 91.8 ± 40.6 |
| percentage of participants | Palivizumab |
|---|---|
| Percentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection | 0 (0.0 to 12.3) |
Percentage of participants who required any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.
| percentage of participants | Palivizumab |
|---|---|
| Intensive-care unit | 0 (0.0 to 12.3) |
| Oxygen supplementation | 0 (0.0 to 12.3) |
| Mechanical ventilation | 0 (0.0 to 12.3) |
| Extracorporeal membrane oxygenation | 0 (0.0 to 12.3) |
| Continuous positive airway pressure | 0 (0.0 to 12.3) |
| Other mechanical respiratory support | 0 (0.0 to 12.3) |
Number of days of hospitalization caused by RSV infection.
No measurements were reported for this outcome.
Duration (days) of requirement for any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.
No measurements were reported for this outcome.
An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.
| participants | Palivizumab |
|---|---|
| Any AE | 27 |
| Any AE at least "possibly" drug related | 0 |
| Any AE at least "probably not" drug related | 7 |
| Any "severe" AE | 2 |
| Any SAE | 7 |
| Any AE leading to discontinuation of study drug | 1 |
| Any AE leading to death | 0 |
| Death | 0 |
| mm Hg | Palivizumab |
|---|---|
| Baseline Systolic Blood Pressure (SBP); n=26 | 96.1 ± 9.44 |
| Change from Baseline in SBP at Day 121; n=26 | -2.4 ± 10.23 |
| Baseline Diastolic Blood Pressure (DBP); n=25 | 55.0 ± 9.16 |
| Change from Baseline in DBP at Day 121; n=25 | 3.0 ± 14.56 |
| degrees Celcius | Palivizumab |
|---|---|
| Baseline Body Temperature (BT) | 36.77 ± 0.346 |
| Change from Baseline in BT at Day 12 | -0.11 ± 0.400 |
| respirations per minute | Palivizumab |
|---|---|
| Baseline Respiratory Rate (RR) | 33.4 ± 8.59 |
| Change from Baseline in RR at Day 121 | 1.5 ± 8.21 |
| beats per minute | Palivizumab |
|---|---|
| Baseline Pulse Rate (PR) | 126.6 ± 21.91 |
| Change from Baseline PR at Day 121 | -6.7 ± 26.66 |
| kilograms | Palivizumab |
|---|---|
| Baseline Body Weight (BW) | 8.76 ± 1.90 |
| Change from Baseline in BW at Day 121 | 1.23 ± 0.71 |
Normal range for hemoglobin varied by the monthly age of the participant.
| g/dL | Palivizumab |
|---|---|
| Baseline Hemoglobin | 11.57 ± 1.56 |
| Change from Baseline in Hemoglobin at Day 121 | 0.14 ± 1.87 |
Normal range for hematocrit varied by the monthly age of the participant.
| percentage of red blood cells | Palivizumab |
|---|---|
| Baseline Hematocrit | 34.32 ± 4.72 |
| Change from Baseline in Hematocrit at Day 121 | 0.96 ± 5.43 |
Normal ranges for WBC, neutrophils, eosinophils, basophils, lymphocytes, and monocytes varied by the monthly age of the participant.
| cells *10^3/µL | Palivizumab |
|---|---|
| Baseline White Blood Cells (WBC); n=25 | 6.74 ± 3.93 |
| Change from Baseline in WBC at Day 121; n=25 | 0.24 ± 2.53 |
| Baseline (BL) Neutrophils; n=24 | 2.60 ± 2.17 |
| Change from BL in Neutrophils at Day 121; n=24 | -0.05 ± 1.60 |
| Baseline Eosinophils; n=24 | 0.25 ± 0.26 |
| Change from BL in Eosinophils at Day 121; n=24 | -0.0 ± 0.31 |
| Baseline Basophils; n=24 | 0.04 ± 0.05 |
| Change from Baseline in Basophils at Day 121; n=24 | 0.02 ± 0.07 |
| Baseline Lymphocytes; n=24 | 3.36 ± 2.35 |
| Change from BL in Lymphocytes at Day 121; n=24 | 0.31 ± 1.69 |
| Baseline Monocytes; n=24 | 0.51 ± 0.44 |
| Change from Baseline in Monocytes at Day 121; n=24 | -0.02 ± 0.38 |
Normal ranges for RBC and platelet count varied by the monthly age of the participant.
| cells *10^4/µL | Palivizumab |
|---|---|
| Baseline Red Blood Cells (RBC) | 410.6 ± 70.83 |
| Change from Baseline in RBC at Day 121 | 22.3 ± 74.74 |
| Baseline Platelet Count | 31.29 ± 19.80 |
| Change from Baseline in Platelet Count at Day 121 | 1.72 ± 18.35 |
Normal ranges for ALP, AST, and ALT varied by the monthly age of the participant.
| U/L | Palivizumab |
|---|---|
| Baseline ALP | 943.0 ± 519.10 |
| Change from Baseline in ALP at Day 121 | -18.0 ± 368.35 |
| Baseline AST | 39.08 ± 12.95 |
| Change from Baseline in AST at Day 121 | 1.54 ± 8.09 |
| Baseline ALT | 31.13 ± 25.70 |
| Change from Baseline in ALT at Day 121 | -3.17 ± 14.07 |
Normal ranges for total bilirubin, BUN, creatinine, and CRP varied by the monthly age of the participant.
| mg/dL | Palivizumab |
|---|---|
| Baseline Total Bilirubin | 0.30 ± 0.14 |
| Change from Baseline in Total Bilirubin at Day 121 | 0.04 ± 0.15 |
| Baseline BUN | 11.46 ± 4.52 |
| Change from Baseline in BUN at Day 121 | 0.87 ± 4.64 |
| Baseline Creatinine | 0.23 ± 0.04 |
| Change from Baseline in Creatinine at Day 121 | 0.01 ± 0.04 |
| Baseline CRP | 0.29 ± 0.42 |
| Change from Baseline in CRP at Day 121 | 0.03 ± 0.62 |
The values -, -/+, 1+, 2+, 3+, and 4+ represent a range from none (-) to highest (4+) presence of protein, glucose, and occult blood in the urine. Table presents the number of participants with each value. Those categories with 0 participants to report at either time point are not included in the table below.
| participants | Palivizumab |
|---|---|
| Protein "-" at Screening; n=24 | 21 |
| Protein "+/-" at Screening; n=24 | 3 |
| Protein "-" at Day 121; n=22 | 21 |
| Protein "+/-" at Day 121; n=22 | 1 |
| Glucose "-" at Screening; n=24 | 24 |
| Glucose "-" at Day 121; n=22 | 22 |
| Occult Blood "-" at Screening; n=24 | 21 |
| Occult Blood "+/-" at Screening; n=24 | 2 |
| Occult Blood "1+" at Screening; n=24 | 1 |
| Occult Blood "-" at Day 121; n=22 | 21 |
| Occult Blood "+/-" at Day 121; n=22 | 0 |
| Occult Blood "1+" at Day 121; n=22 | 1 |
Collected over AEs:from time of initial study drug administration (Day 1) to 100 days after final administration of the study drug. SAEs:from screening period until 100 days after final administration of study drug. Mean (SD) duration of treatment was 183 (37.29) days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palivizumab | — | 7/28 (25%) | 27/28 (96.4%) |
| Event | Palivizumab |
|---|---|
| GastroenteritisInfections and infestations | 3/28 |
| BronchitisInfections and infestations | 2/28 |
| Duodenal StenosisGastrointestinal disorders | 1/28 |
| EnterocolitisGastrointestinal disorders | 1/28 |
| Gastrointestinal PerforationGastrointestinal disorders | 1/28 |
| Croup InfectiousInfections and infestations | 1/28 |
| Infectious PeritonitisInfections and infestations | 1/28 |
| PneumoniaInfections and infestations | 1/28 |
| Pneumonia BacterialInfections and infestations | 1/28 |
| EncephalopathyNervous system disorders | 1/28 |
| Event | Palivizumab |
|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 10/28 |
| EczemaSkin and subcutaneous tissue disorders | 9/28 |
| GastroenteritisInfections and infestations | 7/28 |
| InfluenzaInfections and infestations | 6/28 |
| HypogammaglobulinaemiaImmune system disorders | 5/28 |
| NasopharyngitisInfections and infestations | 5/28 |
| Dermatitis DiaperSkin and subcutaneous tissue disorders | 5/28 |
| RashSkin and subcutaneous tissue disorders | 5/28 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/28 |
| Hepatic Function AbnormalHepatobiliary disorders | 4/28 |
| Age Continuous(months) | Palivizumab |
|---|---|
| Mean | 14.2 ± 6.20 |
| Sex: Female, Male(Participants) | Palivizumab |
|---|---|
| Female | 11 |
| Male | 17 |
| Region of Enrollment(participants) | Palivizumab |
|---|---|
| Japan | 28 |
The record gives a start of Aug 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palivizumab
Respiratory Syncytial Virus Infections →
AbbVie (prior sponsor, Abbott) →